Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ATS Pharmaceuticals, a division of Auriga Laboratories, has launched the Breze Pads for the topical treatment of acne vulgaris.
Subscribe to our email newsletter
Breze Pads (benzoyl peroxide 4.75% and 7.75%) complement the current ATS portfolio which also includes Zytopic (triamcinolone acetonide, 0.1%), Coraz (hydrocortisone lotion USP, 2%), and the Xyralid (lidocaine HCl /hydrocortisone acetate) brand. Breze Pads will be promoted primarily to dermatologists by the ATS Pharmaceuticals.
The topical acne market offers ATS a new opportunity to accelerate existing sales growth in a field where ATS has no previous presence.
Frank Greico, CEO of Auriga, said: “We believe our entry into the acne market further diversifies our revenue base and allows us to expand into a highly attractive market.”